Social Media Posts About Cancer: Five Timepoints
6 mai 2026 mis à jour par: UNC Lineberger Comprehensive Cancer Center
The main purpose of this trial was to evaluate the impact of user interface designs on intervening with cancer misinformation on social media.
The investigators conducted a randomized clinical trial with a sample of 294 US adults (ages 18-65) who previously had a cancer diagnosis or were a cancer caregiver.
This registration record only covers the 5 timepoint trial under the same IRB number.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
This 5 timepoint trial aimed to determine whether user interface designs encouraged intervening and reduced sharing of cancer misinformation on social media. The investigators enrolled 294 adults, ages 18-65, who had received a cancer diagnosis or were a cancer caregiver. Participants completed 5 online surveys, space approximately 2 business days apart. In the first survey, participant were randomized to 1 of 3 trial arms, described below. During each online survey, participants interacted with a simulated social media platform, branded as Invibe. Participants had passive exposure to stimuli cancer misinformation posts and cancer support posts in social media feeds. Participants also had forced exposure to stimuli posts in the online survey after interacting with Invibe. The investigators recorded social media behavior on Invibe and assessed self-reported measures in the online survey.
This study was preregister on AsPredicted.com on March 24, 2025, prior to data collection and data analysis (https://aspredicted.org/te3su2.pdf).
Type d'étude
Interventionnel
Inscription (Réel)
294
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- University of North Carolina at Chapel Hill
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- Are ages 18-65
- Received a cancer diagnosis or have been a cancer caregiver
- Used social media
- Were willing to complete all five study timepoints
- Resided in the United States
Exclusion Criteria:
- Were unable to scroll to see posts on Invibe in the screener survey
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Social cue prompts and policy
Participants are exposed to the social cue prompts and policy intervention with cancer misinformation posts.
|
Cancer misinformation posts are shown with a prompt above the post caption that read, "This post has been flagged as false and potentially harmful by [47 or 48] people on Invibe.
If you want to report, click the flag below."
The social media launch screen had an overlaid policy for removing flagged posts: "We are committed to working with you and others on Invibe to reduce false and potentially harmful information.
When a post is flagged by 50 people, we remove it until we verify the information.
Please help us make the Invibe experience a good one for all."
|
|
Expérimental: Standard prompts
Participants are exposed to the standard prompts intervention with cancer misinformation posts.
|
Cancer misinformation posts are shown with a prompt above the post caption that read, "This post has been flagged as false and potentially harmful.
If you want to report, click the flag below."
|
|
Aucune intervention: Control
Participants do not see prompts on cancer misinformation posts.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Flagging
Délai: Up to 2 weeks
|
Measured with intervening behavior, defined as the flag icon selected.
Response options were no (coded as 0) or yes (coded as 1).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Willingness to flag
Délai: Up to 2 weeks
|
Measured with 1 self-reported survey item: "How willing are you to flag this post?"
Responses ranged from "not at all" (coded as 1) to "extremely" (5).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disliking
Délai: Up to 2 weeks
|
Measured with intervening behavior, defined as the thumbs down icon selected.
Response options were no (coded as 0) or yes (coded as 1).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Liking
Délai: Up to 2 weeks
|
Measured with intervening behavior, defined as the heart icon selected.
Response options were no (coded as 0) or yes (coded as 1).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Willingness to dislike
Délai: Up to 2 weeks
|
Measured with 1 self-reported survey item: "How willing are you to dislike (thumbs down) this post?"
Responses ranged from "not at all" (coded as 1) to "extremely" (5).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Willingness to like
Délai: Up to 2 weeks
|
Measured with 1 self-reported survey item: "How willing are you to like (heart) this post?"
Responses ranged from "not at all" (coded as 1) to "extremely" (5).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Willingness to comment
Délai: Up to 2 weeks
|
Measured with 1 self-reported survey item: "How willing are you to comment on this post?"
Responses ranged from "not at all" (coded as 1) to "extremely" (5).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Willingness to share
Délai: Up to 2 weeks
|
Measured with 1 self-reported survey item: "How likely are you to share or tell someone about this post?"
Responses ranged from "not at all" (coded as 1) to "extremely" (5).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Comment valence
Délai: Up to 2 weeks
|
Measured with 1 self-reported survey item: "What type of comment would you write on this post?"
Response options were "comment to agree" (share), "comment to disagree" (intervene), "other," or "I would not comment."
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Sharing recipient
Délai: Up to 2 weeks
|
Measured with 1 self-report survey item: "Who would you share about this post with?" Response options were "someone with cancer," "someone who is a cancer caregiver," "health-care provider," "other," or "no one."
Assessed 6 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at first timepoint and last timepoint approximately 2 weeks apart.
|
Up to 2 weeks
|
|
Sharing channel
Délai: Up to 2 weeks
|
Measured with 1 self-report survey item: "How would you share about this post?"
Response options were "private message on social media," "text message," "in person," "repost on your social media," "other," and "none of these ways."
Assessed 6 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at timepoint 1 and timepoint 5 approximately 2 weeks apart.
|
Up to 2 weeks
|
|
Past week intervening behavior
Délai: Up to 2 weeks
|
Measured with 1 self-reported survey item: "In the last 7 days, did you take action against false and potentially harmful cancer posts from social media?
Select all that apply."
Response options included muted accounts, flagged posts, disliked posts, commented to correct posts, chatted with others to disagree with posts information, encouraged someone to flag or report a posts, other or did not do anything.
Assessed 1 time.
Assessed at timepoint 4 approximately a week after the day of enrollment
|
Up to 2 weeks
|
|
Past week intervening platform
Délai: Up to 2 weeks
|
Measured with 1 self-reported survey item per reported interpersonal intervening behavior: "Who did you [intervening behavior]?
Select all that apply."
Response options were "someone with cancer," "someone who is a cancer caregiver," "health-care provider," "other," or "no one."
Assessed up to 2 times.
Assessed at timepoint 4 approximately a week after the day of enrollment.
|
Up to 2 weeks
|
|
Past week intervening topic
Délai: Up to 2 weeks
|
Measured with 1 self-reported survey item per reported intervening behavior: "What was the [source for intervening] about?
Select all that apply."
Response options were "to adopt a new mindset," "diet and nutrition advice," "physical activity advice," "advice to stop clinical care," "to seek treatment outside the US," or "other."
Assessed up to 6 times.
Assessed at timepoint 4 approximately a week after the day of enrollment.
|
Up to 2 weeks
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Les enquêteurs
- Chercheur principal: Allison J Lazard, PhD, UNC Lineberger Comprehensive Cancer Center
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
31 mars 2025
Achèvement primaire (Réel)
12 mai 2025
Achèvement de l'étude (Réel)
12 mai 2025
Dates d'inscription aux études
Première soumission
6 mai 2026
Première soumission répondant aux critères de contrôle qualité
6 mai 2026
Première publication (Réel)
15 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
15 mai 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
6 mai 2026
Dernière vérification
1 mai 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 25-0269-5TP
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
OUI
Description du régime IPD
Researcher may request de-identified data from participants 1 year after publication.
Type d'informations de prise en charge du partage d'IPD
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .